All In Biotech

Free tool

FAERS Monitor: Kimmtrak

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761228 or its brand name (Kimmtrak, Tebentafusp-Tebn). Reports on generic versions are filed under their own applications.

Reports

602

Serious

457

76% of reports

Hospitalization

201

Death reported

107

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome118
  • pyrexia107
  • disease progression73
  • hypotension70
  • rash69
  • malignant neoplasm progression61
  • chills59
  • product dose omission issue56
  • pruritus44
  • nausea40
  • vomiting36
  • death32
  • fatigue24
  • hypoxia22
  • diarrhoea20

Reports by year received

View as table
YearReports
20182
2022100
2023104
2024134
2025139
2026123

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,557 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytokine release syndromeSignal118206.7175.823,837
hypoxiaSignal2221.814.5417
disease progressionSignal7321.617.41,418
malignant neoplasm progressionSignal6120.816.41,136
chillsSignal5917.613.8911
hypotensionSignal7012.29.8715
pyrexiaSignal10710.89.1958
product dose omission issueSignal566.75.2267
rashSignal695.54.4257
pruritusSignal444.03.098
vomitingSignal362.71.937
nausea401.81.313
death321.30.92
diarrhoea201.10.70
fatigue241.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.